DOCM Stock Analysis: DocMorris | SW
Pharmaceutical Retailers | SW, Switzerland | Market Cap: 544m CHF | 12M Return: 94.6% | CH0042615283 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.27M
Qual. Beats: 0
Rev. Trend: -3.5%
Warnings
Tailwinds
Seasonality 9.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DocMorris AG is a Swiss online pharmacy, telemedicine, and healthcare company active in Switzerland and internationally. Its offering includes prescription and over-the-counter medicines, consumer health, beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional services to doctors, pharmacies, insurers, and health institutions, distributing under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands. Founded in 1993 and previously known as Zur Rose Group AG, the company adopted its current name in May 2023 and is headquartered in Frauenfeld, Switzerland.
Operating within the GICS Drug Retail sub-industry of the Consumer Staples sector, the company combines a mail-order pharmacy model with B2B services to insurers and health institutions, alongside its TeleClinic telemedicine platform. This hybrid retail-plus-services structure is characteristic of European online pharmacy operators, which have expanded as regulators across the EU and Switzerland have formalized frameworks for the online dispensing of prescription medicines.
- German e-prescription adoption accelerates mail-order prescription volume
- Swiss regulators tighten mail-order pharmacy prescription rules
- Persistent operating losses trigger restructuring and cost reduction
| Net Income: -125.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 10.68 > 1.0 |
| NWC/Revenue: 10.17% < 20% (prev 29.83%; Δ -19.66% < -1%) |
| CFO/TA 0.05 > 3% & CFO 35.0m > Net Income -125.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.9m) vs 12m ago 103.7% < -2% |
| Gross Margin: 3.36% > 18% (prev 22.20%; Δ -18.84% > 0.5%) |
| Asset Turnover: 140.5% > 50% (prev 90.60%; Δ 49.88% > 0%) |
| Interest Coverage Ratio: -9.12 > 6 (EBIT TTM -196.7m / Interest Expense TTM 21.6m) |
| A: 0.16 (Total Current Assets 257.7m - Total Current Liabilities 137.4m) / Total Assets 775.7m |
| B: -1.01 (Retained Earnings -779.6m / Total Assets 775.7m) |
| C: -0.23 (EBIT TTM -196.7m / Avg Total Assets 841.6m) |
| D: 0.86 (Book Value of Equity 357.9m / Total Liabilities 417.8m) |
| Altman-Z'' = -2.93 = D |
| DSRI: 1.12 (Receivables 100.7m/62.3m, Revenue 1.18b/822.1m) |
| GMI: 6.61 (GM 22.20% / 3.36%) |
| AQI: 1.11 (AQ_t 0.62 / AQ_t-1 0.56) |
| SGI: 1.44 (Revenue 1.18b / 822.1m) |
| TATA: -0.21 (NI -125.9m - CFO 35.0m) / TA 775.7m) |
| Beneish M = 2.52 (Cap -4..+1) = D |
As of September 26, 2026, the stock is trading at CHF 11.44 with a total of 439,238 shares traded. Over the past week, the price has changed by +7.12%, over one month by +11.50%, over three months by +40.37% and over the past year by +94.56%.
Current recommended Stop Loss: 10.60 (which is 7.3% or 1.5 ATR below the current price).
DocMorris has no consensus analysts rating.
P/S = 0.4606
P/B = 1.5213
Revenue TTM = 1.18b CHF
EBIT TTM = -196.7m CHF
EBITDA TTM = -151.8m CHF
Long Term Debt = 244.1m CHF (from longTermDebt, last quarter)
Short Term Debt = 4.24m CHF (from shortTermDebt, last quarter)
Debt = 287.2m CHF (from shortLongTermDebtTotal, last quarter) + Leases 21.5m
Net Debt = 197.4m CHF (calculated: Debt 287.2m - CCE 89.8m)
Enterprise Value = 741.9m CHF (544.5m + Debt 287.2m - CCE 89.8m)
Interest Coverage Ratio = -9.12 (Ebit TTM -196.7m / Interest Expense TTM 21.6m)
EV/FCF = 20.79x (Enterprise Value 741.9m / FCF TTM 35.7m)
FCF Yield = 4.81% (FCF TTM 35.7m / Enterprise Value 741.9m)
FCF Margin = 3.02% (FCF TTM 35.7m / Revenue TTM 1.18b)
Net Margin = -10.65% (Net Income TTM -125.9m / Revenue TTM 1.18b)
Gross Margin = 3.36% ((Revenue TTM 1.18b - Cost of Revenue TTM 1.14b) / Revenue TTM)
Gross Margin QoQ = 9.17% (prev -2.61%)
Tobins Q-Ratio = 0.96 (Enterprise Value 741.9m / Total Assets 775.7m)
Interest Expense / Debt = 7.51% (Interest Expense 21.6m / Debt 287.2m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -147.5m (EBIT -196.7m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.87 (Total Current Assets 257.7m / Total Current Liabilities 137.4m)
Debt / Equity = 0.80 (Debt 287.2m / totalStockholderEquity, last quarter 357.9m)
Debt / EBITDA = -1.30 (negative EBITDA) (Net Debt 197.4m / EBITDA -151.8m)
Debt / FCF = 5.53 (Net Debt 197.4m / FCF TTM 35.7m)
Total Stockholder Equity = 391.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.97% (Net Income -125.9m / Total Assets 775.7m)
RoE = -32.21% (Net Income TTM -125.9m / Total Stockholder Equity 391.0m)
RoCE = -30.97% (EBIT -196.7m / Capital Employed (Equity 391.0m + L.T.Debt 244.1m))
RoIC = -25.29% (negative operating profit) (NOPAT -147.5m / Invested Capital 583.4m)
WACC = 7.41% (E(544.5m)/V(831.7m) * Re(8.35%) + D(287.2m)/V(831.7m) * Rd(7.51%) * (1-Tc(0.25)))
Discount Rate = 8.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.58 | Cagr: 37.89%
[DCF] Terminal Value 75.44% ; FCFF base≈35.7m ; Y1≈35.8m ; Y5≈38.0m
[DCF] Fair Price = 7.71 (EV 590.5m - Net Debt 197.4m = Equity 393.0m / Shares 51.0m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -3.47 | Revenue CAGR: -0.50% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-1.72 | Chg30d=+0.12% | Revisions=+17% | GrowthEPS=+50.0% | GrowthRev=+12.2%
EPS next Year (2027-12-31): EPS=-0.93 | Chg30d=+7.61% | Revisions=+50% | GrowthEPS=+45.6% | GrowthRev=+11.4%
[Analyst] Revisions Ratio: +44% (up=5, down=1)